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Rachel F Brem5 and Sidney W Fu1,6*
Abstract
Introduction: Triple-negative breast cancer (TNBC) represents 15 to 20% of all types of breast cancer; however, it
accounts for a large number of metastatic cases and deaths, and there is still no effective treatment. The deregulation
of microRNAs (miRNAs) in breast cancer has been widely reported. We previously identified that miR-638 was one of
the most deregulated miRNAs in breast cancer progression. Bioinformatics analysis revealed that miR-638 directly
targets BRCA1. The aim of this study was to investigate the role of miR-638 in breast cancer prognosis and treatment.
Methods: Formalin-fixed, paraffin-embedded (FFPE) breast cancer samples were microdissected into normal epithelial
and invasive ductal carcinoma (IDC) cells, and total RNA was isolated. Several breast cancer cell lines were used for the
functional analysis. miR-638 target genes were identified by TARGETSCAN-VERT 6.2 and miRanda. The expression of
miR-638 and its target genes was analyzed by real-time qRT-PCR and Western blotting. Dual-luciferase reporter assay
was employed to confirm the specificity of miR-638 target genes. The biological function of miR-638 was analyzed by
MTT chemosensitivity, matrigel invasion and host cell reactivation assays.
Results: The expression of miR-638 was decreased in IDC tissue samples compared to their adjacent normal controls.
The decreased miR-638 expression was more prevalent in non-TNBC compared with TNBC cases. miR-638 expression
was significantly downregulated in breast cancer cell lines compared to the immortalized MCF-10A epithelial cells.
BRCA1 was predicted as one of the direct targets of miR-638, which was subsequently confirmed by dual-luciferase
reporter assay. Forced expression of miR-638 resulted in a significantly reduced proliferation rate as well as decreased
invasive ability in TNBC cells. Furthermore, miR-638 overexpression increased sensitivity to DNA-damaging agents,
ultraviolet (UV) and cisplatin, but not to 5-fluorouracil (5-FU) and epirubicin exposure in TNBC cells. Host cell reactivation
assays showed that miR-638 reduced DNA repair capability in post UV/cisplatin-exposed TNBC cells. The reduced
proliferation, invasive ability, and DNA repair capabilities are associated with downregulated BRCA1 expression.
Conclusions: Our findings suggest that miR-638 plays an important role in TNBC progression via BRCA1 deregulation.
Therefore, miR-638 might serve as a potential prognostic biomarker and therapeutic target for breast cancer.
* Correspondence: sfu@gwu.edu
1Department of Medicine (Division of Genomic Medicine), The George
Washington University School of Medicine and Health Sciences, 2300 Eye St.
NW, Ross Hall 402C, Washington, DC 20037, USA
6Department of Microbiology, Immunology and Tropical Medicine, The
George Washington University School of Medicine and Health Sciences, 2300
Eye St. NW, Ross Hall 402C, Washington, DC 20037, USA
Full list of author information is available at the end of the article
© 2014 Tan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Tan et al. Breast Cancer Research 2014, 16:435
http://breast-cancer-research.com/content/16/5/435
Introduction
Breast cancer is the leading cause of cancer-related deaths
in women [1]. Clinically, this heterogeneous disease is
categorized into four major molecular subtypes: Luminal
A, Luminal B, HER2 type and triple-negative/basal-like.
Triple-negative breast cancer (TNBC) constitutes approxi-
mately 15 to 20% of all breast cancer cases, with the worst
outcome of all subtypes [2]. Systemic treatment for
Luminal A and B is based on inhibitors of ER signaling,
whereas patients with tumors overexpressing HER2 recep-
tor can be treated with HER2-targeting agents. For pa-
tients with TNBC, however, there is no targeted therapy
available, and chemotherapy has limited duration of effect
in later stages of the disease [3].
The precise causes of breast cancer are still unclear.
Epigenetic and genetic alterations have long been thought
of as two related mechanisms in both the initial develop-
ment and in breast cancer progression [4]. Breast cancer
susceptibility gene 1 (BRCA1) is the most well-known
gene linked to breast cancer risk [5,6]. BRCA1 plays mul-
tiple roles in DNA damage response pathways including
DNA double-strand break repair, DNA base-excision re-
pair (BER) [7] and nucleotide-excision repair (NER) [8].
Deficiency in BRCA1 expression tends to exhibit defective
DNA repair, which is a critical mechanism of tumorigen-
esis [9]. Brca1-deficient murine mammary epithelial cells
are more sensitive to anticancer treatment, such as cis-
platin [10].
The crosstalk between the genome and the epigenome
offers new possibilities for diagnosis and therapy [11]. Epi-
genetics has been extended to microRNAs (miRNAs). Ma-
ture miRNAs are single-stranded RNA molecules of about
18 to 24 nucleotides, which are endogenously stable and
evolutionarily conserved molecules regulating target gene
expression [12]. miRNA signatures are associated with
clinicobiological features of breast cancer [13,14]. The
advantage of miRNA approaches is based on its ability to
concurrently target multiple effectors of pathways. Due to
their stability and size, miRNAs can be readily extracted
from formalin-fixed, paraffin-embedded (FFPE) samples,
or circulating blood as stable markers for cancer detection
[15]. miRNA-based anticancer therapies have recently
been explored, either alone or in combination with
current targeted therapies [16].
Breast cancer is a genetically and phenotypically com-
plex disease [17]. The classic linear multi-step model of
breast cancer progression has been observed based on his-
tomorphological and epidemiological data. The earliest
neoplastic stage of progression is atypical ductal hyperpla-
sia (ADH), in which molecular alterations occur in breast
epithelium of a normal terminal duct lobular unit. Subse-
quent molecular alterations occur in ADH, resulting in
ductal carcinoma in situ (DCIS), another early neoplastic
stage, upon which additional events occur, resulting in
invasive ductal carcinoma (IDC) [18]. In our previous
work, we identified deregulated miRNAs in the progres-
sion of breast cancer development using FFPE samples
from breast cancer tissue. We found that miR-21, miR-
200b/c, miR-141, and miR-183 were consistently upregu-
lated in ADH, DCIS and IDC compared to normal, while
miR-638 was uniquely downregulated in ADH and DCIS
[19]. Differentially expressed miR-638 has been detected
in the majority of tumors [20-25]. More interestingly, up-
regulation of miR-638 could be a biomarker in response
to DNA damage [26]. In the present study, we aim to
understand the molecular mechanisms of miR-638 de-
regulation in breast cancer by investigating its effects on
proliferation, invasion, DNA repair and sensitivity to anti-
cancer drugs/UV light in breast cancer, with a particular
focus on TNBC.
Materials and methods
FFPE breast cancer samples and microdissection
The tissue blocks were retrieved from the tissue repository
of the Armed Forces Institute of Pathology (AFIP) with its
IRB (Institutional Review Board) approval. This study was
approved by the IRB of the George Washington Univer-
sity. All specimens are anonymized and not coded; there-
fore they cannot be linked back to the individual subject
identities in any way. No consent was needed for this
study. The FFPE blocks were subject to microdissection
into IDC and normal components as described previously
[19].
Breast cancer cell lines and cell culture
The human breast cancer cell lines, MDA-MB-231,
Hs578T, MCF-7 and T47D were purchased from the
American Type Culture Collection (ATCC), and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
(Lonza Group Ltd, Basel, Switzerland) supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin
and streptomycin antibiotics. Immortalized MCF-10A
cells were cultured in mammary epithelial cell growth
medium (MEGM) (CC-3150, Lonza) containing 100 ng/
ml of cholera toxin to make a complete growth culture
medium. All cell lines were grown in a 37°C humidified
incubator with 5% CO2.
Total RNA extraction
Total RNA was isolated from the breast cancer cells, in-
cluding the transfected lines using the Trizol reagent
(Life Technologies, Carlsbad, CA, USA) following the
manufacturer’s instructions. The Recover All Total Nu-
cleic Acid Isolation Kit (AM1975, Ambion Diagnostics,
Austin, TX, USA) was used to isolate total RNA from
the FFPE samples as described earlier [19]. Briefly, 1 ml
of xylene was added to four 20 μm FFPE sections to
remove paraffin. The tissue was digested with proteinase
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K at 55°C overnight and then treated with DNase I. After
washing, total RNA, including the small miRNA fraction,
was reconstituted in distilled water. Quantity and quality of
the total RNA samples were assayed by the NanoDrop1000
Spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA).
Quantitative real-time reverse transcription-PCR
(qRT-PCR) assay
The Taqman MiRNA Reverse Transcript Kit (Applied Bio-
systems, Foster City, CA, USA), which features a stem-
loop RT primer specifically hybridizing with a miRNA was
used. The reverse transcription was performed using the
MultiScribe Reverse Transcriptase. Specifically, 10 ng of
the total RNA was used to start the RT step following the
manufacturer’s protocol. The RT reactions were carried
out at 16°C for 30 minutes, 42°C for 30 minutes, 85°C for
5 minutes and then held at 4°C. To verify miRNA expres-
sion, a final volume of 20 μl for each PCR reaction mix-
ture consisting of 10 μl TaqMan Universal Master Mix II
with no UNG (Applied Biosystems), 1 μl of 20 x Taqman
miR-638 PCR primer (Ambion), 2 μl of 1:1 diluted RT
products and 7 μl nuclease-free water. qPCR was per-
formed using the ABI 7300 Real-Time PCR System (Ap-
plied Biosystems). The conditions for qPCR were 95°C for
10 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 60 seconds. The mean quantity values of the
miRNA expression were normalized by U6 snRNA. Pri-
mer sequences are available upon request.
miRNA target analysis
The potential target genes of miR-638 were analyzed using
the TARGETSCAN-VERT 6.2 [27] and miRanda, which
help identify targets based on comparative sequence
analysis, seed match complementation and Z-score for
assigned untranslated regions (UTRs) and coding sequence
(CDS) region. A group of selected target genes were further
analyzed.
Dual luciferase reporter assay
The 3′-untranslated region (3′-UTR) of the BRCA1-
wild-type (W) or -mutant (M) was cloned to the firefly
luciferase-expressing vector, pEZX-MT05 (Genecopoeia,
Rockville, MD, USA). The BRCA1-W and -M CDS of
miR-638 binding site was constructed in pGL3 plasmid
(a gift from Dr. Wen Chen from Sun Yat-sen University,
China). For the luciferase assay, cells (7 × 105 cells per
well in a 24-well plate) were co-transfected with the 3′
UTR or CDS of BRCA1 reporter vector and miR-638
mimics or the control vector pEZX-MT05 negative-
control (mock) using FuGENE Transfection Reagent
(Promega, Madison, WI, USA). Luciferase activities were
determined with the Dual-Luciferase Reporter System
(Genecopoeia). Each sample was measured in triplicate
using the Glomax Luminometer (Promega).
Protein extraction and Western blot analysis
Proteins were extracted from cell lines using RIPA Buffer
(Thermo Fisher Scientific) according to the manufactur-
er's protocol. Proteins were separated by SDS-PAGE using
a 4 to 15% Mini-PROTEAN TGX™ Precast Gel (Bio-Rad
Laboratories, Hercules, CA, USA) and transferred over-
night at 30 V in a 4°C cold room. The membrane was
blocked prior to the addition of the primary antibody with
5% milk in Tris-buffered saline (TBS) with 0.05% Tween
20. The membrane was incubated overnight with either
BRCA1 rabbit polyclonal antibody (9010S, Cell Signaling
Technology, Danvers, MA, USA) at a dilution of 1:1000 in
TBS buffer with 0.05% Tween and 5% milk, or GAPDH
(MA5-15738) mouse monoclonal antibody (Sigma-Al-
drich, St Louis, MO, USA) at a dilution of 1:2,000 in TBS
buffer with 0.05% Tween. The membrane was washed
three times with TBS/0.05% Tween and incubated with
anti-rabbit immunoglobulin G (IgG) conjugated to horse-
radish peroxidase (7074S, Cell Signaling) for BRCA1, anti-
mouse IgG (7076S, Cell Signaling) for GAPDH at a
1:2,000 dilution in TBS/0.05% Tween and 5% milk. The
Super Signal WestFemo Maximum Sensitivity Substrate
(Thermo Fisher Scientific) was used according to the
manufacturer's protocol to visualize protein expression
and the band intensities were quantified by the ImageJ
software.
Transfection of miR-638 mimic and miR-638 inhibitor in
human breast cancer cell lines
Using transient transfection, 2.4 × 105 cells of each cell
line were seeded in a 6-well plate, cultured in DMEM
medium supplemented with 10% FBS in a 37°C humidi-
fied incubator with 5% CO2. After overnight incubation,
cells reached 30% to 50% confluence and were transi-
ently transfected with miR-638 mimic, miR-638 inhibitor
or mock (Ambion) by Lipofectamine RNAiMAX reagent
(Life Technologies) using the Opti-MEM medium (Life
Technologies). Cells were subjected to further analysis
after 24 h transfection.
Matrigel invasion assay
Matrigel invasion assays were performed using the BD
BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences,
Franklin Lakes, NJ, USA) as previously described [28]. BD
BioCoat Matrigel Invasion Chambers provide cells with
the conditions that allow assessment of their invasive
property in vitro. It consists of a BD Falcon™ TC Compan-
ion Plate with Falcon Cell Culture Inserts containing an 8
micron pore size PET membrane with a thin layer of
matrigel basement membrane matrix. Briefly, prior to the
start of each experiment, 500 μl of warm (37°C) serum-
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free DMEM medium was added to the upper and lower
chambers and allowed to rehydrate for 2 h in a 37°C cell
culture incubator. After 2 h rehydration, the medium was
removed from the upper and lower chambers, 750 μl of
DMEM with 10% FBS and 0.1% bovine serum albumin
(BSA) was added to the pre-wetted lower chambers. Then
2.5 × 104 cells for MDA-MB-231, 3 × 104 for Hs578T,
5 × 104 for MCF-7, 8 × 104 for T47D, transfected by either
miR-638 or mock for 24 h were seeded onto the top
chamber of pre-wetted inserts, cultured in 500 μl serum-
free DMEM with 0.1% BSA in the top chamber. Cells were
incubated in a matrigel chamber in a 37°C humidified in-
cubator with 5% CO2 for 24 h for MDA-MB-231 and 48 h
for Hs578T, MCF-7 and T47D. Next, the noninvasive cells
were removed from the upper surface of the membrane
by scrubbing with a cotton swab and the invasive cells
present on the bottom of the membrane were fixed,
stained with the Diff-Quick staining solution and counted
(five microscope fields under the 10X lens). Experiments
were done in duplicate for each cell line twice. Cell counts
were performed on five non-overlapping random fields for
each chamber, and four chambers were counted for each
experimental point. The percentage of invasive cells was
normalized to the corresponding control.
UVC/chemosensitivity and MTT assays
The miR-638 mimic or mock transfected cells were
washed with phosphate-buffered saline (PBS) 100 μl of
MTT working solution (5 mg/ml stock MTT diluted in
the Opti-MEM media to 0.5 mg/ml working solution)
was added to each well and incubated at 37°C with 5%
CO2 for 3 h. The MTT solution was carefully removed
and 100 μl DMSO was added to each well and incubated
in a 37°C humidified incubator with 5% CO2 for 30 min.
Color development was measured using a spectropho-
tometer at 570 nm on a plate reader (Bio-Tek Instru-
ments, Winooski, VT, USA) and quantified following the
manufacturer’s protocol (Promega). For the MTT che-
mosensitivity assay, cells were treated with UVC (10 J/
m2) and various concentrations of cisplatin (0.5 to 8 μg/
mL), 5-fluorouracil (5-FU, 5 to 400 μg/mL), or epirubi-
cin (0.025 to 1.6 μg/mL). After 48 h, MTT solution was
added and absorbance was measured.
Plasmid treatment with UV light and anticancer drugs
and host cell reactivation assay
pCMVLuc reporter gene plasmid (a kind gift from Dr.
Kenneth H. Kraemer, National Cancer Institute, NIH)
was dissolved in 10 mm Tris-HCl, 1 mm EDTA, pH 8
(TE buffer) to a final concentration of 100 μg /ml and
poured in a petri dish to form a one-dimensional 2 mm
thick layer. The petri dish was placed on ice and irradi-
ated by 1,000 J/m2 of UV light. For the drug treatment,
1 μl aliquots of a stock solution of 1 μg/μl cisplatin,
10 μg/μl 5-FU and 0.01 μg/μl epirubicin (Sigma-Aldrich)
in TE were added to 10 μg plasmid DNA dissolved in
200 μl TE buffer and the samples were incubated at 37°C
for the 6 hours. At the end of the incubation period, 1 M
NaCl was added to a final concentration of 0.2 M NaCl.
The plasmid DNA was precipitated with 2 volumes of
ethanol, washed with 70% ethanol before dissolving in TE
buffer.
DNA repair capability of cells was assessed using the
host cell reactivation (HCR) assay with the pCMVLuc
reporter gene plasmid treated by UV or anticancer drugs
[29]. Briefly, 4 μl (200 ng) of CsCl-purified pCMVLuc
damaged or non-damaged were co-transfected with 50
nM miR-638 mimic into cells using Lipofectamine 2000
(Invitrogen). To estimate the DNA repair capacity after
miR-638 knockdown, we co-transfected pCMVLuc with
50 mol of miR-638 inhibitor. Relative luciferase activities
are presented as a percentage of activities obtained with
treated versus untreated control plasmids.
Statistical analysis
Data was expressed as mean ± standard error (SE). Permu-
tation test was performed for MTT assay between control
and miR-638 mimic transfected groups. The Student’s t
test (two-tailed) was applied to the matrigel assays
between control and miR-638 transfected groups. P value
less than 0.05 or 0.01 was considered statistically sig-
nificant and presented with one and two asterisks
respectively.
Results
Decreased expression of miR-638 in breast cancer
In our previous work, we found that miR-638 expression
was decreased in both ADH and IDC stages in breast
cancer [19]. To further evaluate the relationship between
miR-638 expression and progression of breast cancer, we
examined miR-638 expression in 30 breast cancer sam-
ples after microdissecting into normal and IDC compo-
nents (Figure 1A) by qRT-PCR. Downregulated miR-638
expression was detected in 18 of 30 (60%) cases, includ-
ing 15 of 20 (75%) non-TNBC and 3 of 10 (30%) TNBC
cases compared with their adjacent normal samples
(Figure 1B). Thus, deregulation of miR-638 is more
prevalent in non-TNBC compared to TNBC cases.
Next, we analyzed the expression of miR-638 in the
following cell lines, including TNBC lines, MDA-MB-
231, Hs578T and MDA-MB-468 and non-TNBC lines,
MCF-7 and T47D in comparison to the normal immor-
talized MCF-10A cells. We found that miR-638 expres-
sion in all breast cancer cell lines was relatively low
compared to that in MCF-10A cells (Figure 1C). This
data indicates that miR-638 might be a tumor suppres-
sor in breast cancer.
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miR-638 target gene identification
TargetScan and miRanda were used to identify target
genes for miR-638 (miRbase.org website). We obtained a
list of target genes with the information pertaining to the
binding sites for miR-638, including BRCA1 (Table 1). To
identify the common target genes for miR-638, we nar-
rowed down the functional pathway enrichment analysis
using two different algorithms. Since BRCA1 is a multi-
functional tumor suppressor protein and plays multiple
roles in DNA damage response pathways, we focused on
BRCA1 as a target gene for this study.
miR-638 exerted diverse effects on BRCA1 expression
depending upon the subtypes of breast cancer cell lines
To validate the computational predictions and the bio-
logical effect of miR-638 targeting BRCA1, we carried out
in vitro luciferase reporter assays. miR-638 has been
reported to inhibit BRCA1 expression by targeting BRCA1
in CDS but not in the 3’ UTR [30]. We performed lucifer-
ase reporter assay with the pGL3 plasmid containing miR-
638-binding site in BRCA1 CDS region (Figure 2A). We
found that the luciferase activities vary in different breast
cancer cell lines after successful transfection of miR-638
mimics (Figure 2B). Luciferase activities were significantly
decreased in miR-638-transfected TNBC cell lines MDA-
MB-231 and Hs578T, but not in estrogen receptor (ER)-
positive cell lines T47D and immortalized MCF-10A cells.
Inversely, the luciferase activities were significantly in-
creased in miR-638-transfected MCF-7 cells. There was
no significant difference in luciferase activities between
controls and mutant miR-638 transfectants (Figure 2B).
Inconsistent with the luciferase assay results, significant
downregulation of BRCA1 was observed in TNBC cell
lines MDA-MB-231 and Hs578T, but upregulation of
Figure 1 Expression of miR-638 in breast cancer tissue samples and cell lines. (A) Representative images before microdissection. Breast cancer
tissue sections were double immunostained for smooth muscle actin (red) to elucidate the epithelial capsule (arrows). Different components, such as
normal (N), ADH, DCIS and IDC are as indicated. (B) Expression of miR-638 in TNBC and non-TNBC cases. Expression of miR-638 was significantly
downregulated in 3 of 10 TNBCs and 15 of 20 non-TNBCs when compared to normal. (C) Expression of miR-638 in breast cancer cell lines was
downregulated compared to the immortalized MCF-10A cells. Results are displayed as mean data ± SE. (*P <0.05 and **P <0.01). ADH, atypical
ductal hyperplasia; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; TNBC, triple-negative breast cancer.
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BRCA1 was shown in ER-positive cell lines, MCF-7 and
T47D (Figure 2C). These results demonstrate that
miR-638 may specifically regulate BRCA1 in TNBC, not
in ER + cells, which suggests that the function of miR-638
might be blocked or antagonized by hormonal receptor
expression.
Overexpression of miR-638 inhibited proliferation in
TNBC cell lines
Since the expression of miR-638 was significantly lower in
both breast cancer cell lines and tissues compared to nor-
mal cells and tissues, we next focused on the functional ef-
fects of miR-638 on breast cancer cells. To address this,
Table 1 A representative list of target genes for miR-638
Target gene Representative
transcript
Gene name Conserved
sites
Total context +
score
Total 8-mer 7mer-m8 7mer-1A
STARD10 NM_006645 StAR-related lipid transfer (START)
domain containing 10
1 1 0 0 −0.53
NPAS4 NM_178864 neuronal PAS domain protein 4 1 1 0 0 −0.44
MKLN1 NM_001145354 muskelin 1, intracellular mediator
containing kelch motifs
1 0 0 1 −0.27
CCDC92 NM_025140 coiled-coil domain containing 92 1 0 0 1 −0.26
SHPK NM_013276 sedoheptulokinase 1 0 0 1 −0.26
RIMKLB NM_020734 ribosomal modification protein
rimK-like family member B
1 0 1 0 −0.24
PGK1 NM_000291 phosphoglycerate kinase 1 1 0 0 1 −0.22
HP1BP3 NM_016287 heterochromatin protein 1, binding
protein 3
1 0 0 1 −0.21
LMO4 NM_006769 LIM domain only 4 1 0 0 1 −0.21
PAK2 NM_002577 p21 protein (Cdc42/Rac)-activated
kinase 2
1 0 0 1 −0.2
MARCKS NM_002356 myristoylated alanine-rich protein
kinase C substrate
1 0 0 1 −0.19
FRMPD4 NM_014728 FERM and PDZ domain containing 4 1 0 0 1 −0.18
EMILIN3 NM_052846 elastin microfibril interfacer 3 1 0 0 1 −0.18
MYCL1 NM_001033081 v-myc myelocytomatosis viral
oncogene homolog 1, lung carcinoma
derived (avian)
1 0 0 1 −0.18
LOC100507050 NM_001195528 hypothetical LOC100507050 1 0 0 1 −0.18
ISOC2 NM_001136201 isochorismatase domain containing 2 1 0 0 1 −0.18
EDN3 NM_207032 endothelin 3 1 0 0 1 −0.18
BRCA1 NM_007294 breast cancer 1, early onset 1 0 0 1 −0.16
TSPAN1 NM_005727 tetraspanin 1 1 0 0 1 −0.16
BUB3 NM_004725 budding uninhibited by
benzimidazoles 3 homolog (yeast)
1 0 0 1 −0.15
SP8 NM_182700 Sp8 transcription factor 1 0 0 1 −0.15
ZNF24 NM_006965 zinc finger protein 24 1 0 0 1 −0.14
KDSR NM_002035 3-ketodihydrosphingosine reductase 1 0 0 1 −0.14
KPNA6 NM_012316 karyopherin alpha 6 (importin alpha 7) 1 0 0 1 −0.13
SP7 NM_001173467 Sp7 transcription factor 1 0 0 1 −0.12
NOVA1 NM_002515 neuro-oncological ventral antigen 1 1 0 0 1 −0.11
SENP1 NM_014554 SUMO1/sentrin specific peptidase 1 1 0 0 1 −0.06
SRSF1 NM_001078166 serine/arginine-rich splicing factor 1 1 0 0 1 −0.05
EPHA7 NM_004440 EPH receptor A7 1 0 0 1 −0.04
TTC28 NM_001145418 tetratricopeptide repeat domain 28 1 0 0 1 −0.04
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miR-638 mimic, miR-638 inhibitor or mock control was
transfected into breast cancer cells. The cellular prolifera-
tion rate of breast cancer cell lines was determined by
MTT assay. As expected, overexpression of miR-638
inhibited proliferation in TNBC cell lines, MDA-MB-231
and Hs578T, while increased cell growth in ER-positive
MCF-7 cells, and had almost no effect in T47D cells com-
pared to the mock-transfected control cells (Figure 3A).
Conversely, transfection of miR-638 inhibitor resulted in
an increased cell growth in MDA-MB-231 and Hs578T
cells and a decreased cell growth in MCF-7 and no signifi-
cant change in T47D cells. Surprisingly, decreased cell
proliferation was also observed in miR-638-transfected
MCF-10A cells, which are defined as ‘normal’ breast epi-
thelial cells. However, there was no significant difference
when miR-638 inhibitor was transfected into MCF-10A
cells. These results demonstrate that miR-638 can inhibit
cell proliferation in TNBC but not in ER-positive breast
cancer cells, suggesting that overexpression of miR-638
may be a promising therapeutic option for TNBC. The
downregulation of miR-638 could be a prognostic indica-
tor for the aggressiveness.
Overexpression of miR-638 affected invasion ability in
breast cancer cell lines
To determine if overexpression of miR-638 affects the inva-
sive ability of breast cancer cell lines, cell invasion assay
was performed using the BD matrigel. We found that miR-
638-overexpressing TNBC cell lines exhibited significant
inhibition of invasion ability (60% in MDA-MB-231 and
70% in Hs578T) compared to the control. For ER-positive
cell lines, miR-638-overexpressing MCF-7 cell line showed
no invasion changes (P = 0.90) while T47D decreased its
invasion activity, compared to the control (P = 0.47)
(Figure 3B and C). This data suggests that miR-638 plays
an important role in cell invasion, specifically in TNBC.
Overexpression of miR-638 sensitizes the TNBC cell lines
to DNA-damaging agents
Overexpression of BRCA1 in MCF7 cell line has been re-
ported to result in an increased resistance to cisplatin [31].
Based on our evidence, we reasoned that overexpression of
miR-638 could sensitize TNBC cells to DNA-damaging
agents by means of their ability to reduce BRCA1 expres-
sion and curb the activation of BRCA1 in TNBC cells. To
evaluate this hypothesis, we treated breast cancer cells
transfected with miR-638 mimic or inhibitor (Figure 4A)
with DNA-damaging agents (UVC, cisplatin and 5-FU) and
non-DNA-damaging agents (epirubicin). UVC/chemosensi-
tivity was determined by the MTT assay 48 hours after
treatment. As shown in Figure 4B and C, miR-638 expres-
sion significantly increased sensitivity to UV and cisplatin
in TNBC cell lines MDA-MB-231 and Hs578T, but re-
duced sensitivity in MCF-7 cells as compared with mock.
Interestingly, a similar effect of cisplatin was observed in
MCF-10A cells. The effect of miR-638 on sensitivity of UV
and cisplatin was not observed in ER-positive cell line,
T47D. Conversely, knockdown of miR-638 using miR-638
inhibitor increased cell viability in MDA-MB-231 and
Hs578T cells after treatment with UV and cisplatin. It is
notable that miR-638 introduction did not change the sen-
sitivity to 5-FU and epirubicin in breast cancer cell lines
(Figure 4D and E). These results suggested that the inhib-
ition of miR-638 increased sensitivity to partial of DNA-
damaging agents in TNBC but not in non-TNBC cells.
miR-638 overexpression significantly reduced post-UV/
drugs host cell reactivation activity in TNBC cells
miR-638 is involved in DNA repair pathway regulation dur-
ing carcinogen exposure [26]. BRCA1 appears to promote
cell survival after DNA damage by participating in repair
pathways [32]. We then asked whether the deregulation of
miR-638 increases the sensitivity of the TNBC cell lines to
cisplatin and UV via the DNA repair pathway. We mea-
sured luciferase activity by co-transfecting miR-638 mimic
or inhibitor, along with pCMU-Luc vector [29], which was
pre-treated by UVC, DNA-damaging and non-DNA-
damaging agents respectively into the breast cancer cell
lines. For UV and cisplatin exposure, we found that TNBC
cell lines MDA-MB-231 and Hs578T exhibited significantly
reduced luciferase activity, while MCF-7 cell lines showed
opposite effect. There were no changes in luciferase activity
for T47D cells (Figure 5A and B). Conversely, contrary effect
on DNA repair capability was observed in MDA-MB-231,
(See figure on previous page.)
Figure 2 miR-638-mediated regulation of BRCA1 in breast cancer cell lines. (A) The top part shows the predicted location of the miR-638
binding site of the 3’-UTR of BRCA1. The bottom part indicates the binding site in the CDS of BRCA1 (BRCA1 CDS) as well as the mutant BRCA1
sequence (BRCA1 CDS mut) corresponding to miR-638 sequence, along with the pGL-3 vector. (B) Relative luciferase activity was measured in breast
cell lines co-transfected with either 200 ng of miR-638 mimic (dark bars) or a scrambled control (white bar), 100 ng of either pGL3-BRCA1-CDS
(BRCA1-wt) or pGL3-BRCA1-CDS mut (BRCA1-mu) by Lipofectamine 2000 (Life Technologies) for 48 h. The data was reported as mean ± SE for three
independent experiments. The luciferase activity was significantly decreased in MDA-MB-231 and Hs578T cells when co-transfected with miR-638
mimic and BRCA1-wt (*P <0.05), while either increased in MCF-7 or not changed in T47D and MCF-10A cells. (C) The expression of BRCA1 protein in
breast cancer cells when transfected with miR-638 mimic (OV) compared to the mock (Mock). BRCA1 expression was significantly downregulated by
miR-638 in TNBC cells, MDA-MB-231 and Hs578T compared to non-TNBC cells, MCF-7 and T47D. The experiments were repeated three times. Band
intensities were quantified using the ImageJ software, and the relative expression level was shown in a bar graph. BRCA1, breast cancer susceptibility
gene 1; CDS, coding sequence; TNBC, triple-negative breast cancer; UTR, untranslated region.
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Hs578T and MCF-7 cells after co-transfection of miR-638
inhibitor and the pCMU-Luc vector pre-treated with
UVC and cisplatin. Our data indicates that miR-638 im-
pairs the DNA repair capability by regulating BRCA1 ex-
pression in TNBC cell lines.
For 5-FU exposure, reduced DNA repair capability
was only observed in Hs578T cells but not in MDA-MB-
231, MCF-7 and T47D cells when co-transfected with
miR-638 mimic and pCMU-Luc vector pre-treated with
5-FU. No significant DNA repair capability changes were
Figure 3 miR-638 modulates proliferation in breast cancer cells and inhibits invasive ability in TNBC cells. (A) Effects of miR-638 on cell proliferation
were determined by MTT assay. The proliferation rate decreased after transfection of miR-638 mimic (gray bars) in TNBC cell lines MDA-MB-231 and Hs578T
as well as in MCF-10A, and increased in MCF-7 cells, and had no effect in T47D cells, compared to the mock control (white bars). Transfection of miR-638
inhibitor (dark bars) promoted proliferation in TNBC cell lines, MDA-MB-231 and Hs578T, but inhibited proliferation in MCF-7 cells compared to the mock.
There were no obvious changes in T47D cells in either mimic or inhibitor transfection, while MCF10A exhibited similar pattern as TNBC cells. Values represent
the mean± SE for three independent experiments. (*P <0.05). (B) Transwell assays with matrigel were performed for the invasion activity of breast cancer cells
transfected with either miR-638 mimic or the mock control. Overexpression of miR-638 reduces cell invasion in TNBC cell lines, MDA-MB-231 and Hs578T, but
not in ER-positive cells, MCF-7 and T47D. (C) Invasion ability of the cells was displayed as a percentage of the absolute cell numbers. Results are displayed as
mean data ± SE. (*P <0.05 and **P <0.001). Five fields of unit area on each membrane or whole membrane were counted for cell numbers, and the
experiments were repeated three times in triplicate. ER, estrogen receptor; TNBC, triple-negative breast cancer.
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observed in cell lines when co-transfected with miR-638
mimic, and pCMU-Luc vector pre-treated with epirubi-
cin. On the other hand, DNA repair capability did not
change when co-transfected miR-638 inhibitor and
pCMU-Luc pre-treated with either 5-FU or epirubicin.
Our results demonstrate that the miR-638 exerts a dis-
tinct effect on DNA repair toward anticancer drugs in
TNBC and ER-positive breast cancer cells.
Discussion
The objective of this study was to decipher the role of
miR-638 in breast cancer tumorigenesis and treatment.
We revealed a dynamic miR-638 expression during the
process of breast cancer progression. In addition, we
demonstrated that different expression patterns of miR-
638 are correlated with its functions in different types of
breast cancer cells. Moreover, we found that the role of
miR-638 on tumorigenesis, radiation and drug sensitivity
was mediated by targeting BRCA1 through DNA repair
pathway. Our results suggest that aberrant expression of
miR-638 contributes to human breast cancer progres-
sion, invasion and sensitivity of radiation and chemo-
therapy, particularly in TNBC.
miR-638 expression changes during development of
breast cancer
miRNA may exhibit different expression levels between
normal and cancer cells [33]. For example, miR-142-3p
and miR-9 were upregulated in squamous cell carcinoma
in comparison to normal bronchial tissues. The alterations
of miRNA expression were probably correlated with the
pathways maintaining the malignant phenotypes or clin-
ical outcomes [26]. miR-638 has been characterized to be
downregulated in majority of tumors, but upregulated in
hepatocellular liver cancer. Our previous data indicated
that miR-638 was downregulated in ADH and IDC during
the breast cancer developing stages compared to normal
breast tissues [19]. In this study, we analyzed miR-638
expression in a new cohort of 30 breast cancer FFPE
samples. We showed that downregulation of miR-638 pre-
sented in the majority of the IDCs compared to their adja-
cent normal tissues. These results support the notion that
dysfunction of miR-638 is essential in maintaining the ma-
lignant phenotype of cancer. A larger cohort study will
help understand the exact role of miR-638 in breast can-
cer development and progression. In addition, we assessed
the expression of miR-638 in breast cancer cell lines. The
expression of miR-638 was low in breast cancer cell lines
compared with the MCF-10A cells (Figure 1C). Based on
these data, we hypothesize that deregulation of miR-638 is
involved in the process of breast cancer progression.
miR-638 is a double-faced gene expression regulator
It is currently believed that miRNAs elicit their effect by
silencing the expression of target genes [34]. However,
miRNAs may also function to positively regulate gene
expression [35,36]. miR-638 has been reported to inhibit
BRCA1 expression in different cancer cell lines by tar-
geting BRCA1 in CDS, but not in 3’ UTR [30]. In our
study, overexpression of miR-638 suppressed BRCA1 ex-
pression in TNBC cells, MDA-MB-231 and Hs578T, but
not in ER-positive cell lines. These data support the no-
tion that miR-638 exerts diverse effects depending upon
breast cancer types. Since TNBC lacks expression of ER,
PR and HER2, we believe that hormones might be in-
volved in miR-638-mediated BRCA1 regulation, which
requires further studies. Nicoloso et al. observed an op-
posite BRCA1 regulation of miR-638 in MCF-7 cells
[30]. A possible explanation might be that miR-638 ex-
hibits distinct BRCA1 regulation in cell populations with
different phases of cell cycle. Our data suggests that
miR-638 elicits differential efficacy by silencing or indu-
cing the expression of BRCA1 in different breast cancer
cell lines. These findings demonstrate that miR-638 ex-
hibits a dual function in response to environmental
stimuli depending upon the state of cell malignancy. It
might be a useful biomarker for surveillance of chemical
exposure in breast cancer treatment.
miR-638 plays an important role in cell proliferation
and invasion
Previous studies have demonstrated that miR-638 regu-
lates cell growth and smooth muscle cell proliferation and
migration [37], and negatively regulates BRCA1 expres-
sion. In esophageal squamous cell carcinoma, miR-638
promotes cell proliferation in vitro [23]. We analyzed the
functional consequences after overexpressing miR-638 in
breast cancer cell lines. Our data indicated that miR-638
has different functions on cell behaviors in different types
of breast cancer cells. miR-638 inhibited cell proliferation
in TNBC cells, while promoted cell proliferation in ER-
positive cells. Interestingly, miR-638 exerts similar effect
(See figure on previous page.)
Figure 4 Effect of miR-638 on sensitivity of breast cancer cell lines to anticancer drugs or UV treatment. miR-638 expression in breast cancer
cell lines transfected with miR-638 mimic or inhibitor compared to the mock control was examined by qRT-PCR (A). Twenty-four h after transfection of
miR-638 mimic, miR-638 inhibitor or mock, cells were treated by UVC, cisplatin, 5-FU and epirubicin, respectively for 48 h. Cell sensitivity was measured
by MTT assay. miR-638 expression significantly increased sensitivity to UV (B) and cisplatin (C) in TNBC cell lines, MDA-MB-231 and Hs578T, but reduced
sensitivity in MCF-7 cells compared with the mock. miR-638 expression did not change the sensitivity to 5-FU (D) and epirubicin (E) in breast cancer
cell lines. Results are displayed as mean data ± SE. *P <0.05, in comparison to the mock. 5-FU, 5-fluorouracil; TNBC, triple-negative breast cancer.
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on inhibiting proliferation in MCF-10A, which is defined
as ‘normal’ breast epithelial cells. Although MCF-10A is
non-tumorigenic, it is a triple-negative human breast cell
line [38]. Our data supports that miR-638 inhibits cell
proliferation in TNBC.
Importantly, miR-638 also alters cell invasion ability.
The invasion was decreased in TNBC cell lines after
miR-638 overexpression, but increased in MCF-7 cells.
We hypothesize that miR-638 functions as a tumor-
suppressor or oncomir in different types of breast cancer
cells or stages during breast cancer progression. How-
ever, miR-638 also suppresses the invasion in T47D cells
although no significant downregulation of BRCA1 was
observed. The possibility might be that miR-638 regu-
lates invasion in T47D via other pathways instead of
BRCA1-related DNA repair pathway.
miR-638 is associated with radiation and chemotherapy
sensitivity of breast cancer cell lines via DNA repair
pathway
miRNAs has been implicated in response to DNA damage
and repair. Some miRNAs are involved in DNA damage re-
sponse and/or DNA repair, which would affect cellular sen-
sitivity to DNA-damaging agents [39]. In order to explore
whether miR-638 expression could be used as a biomarker
for predicting tumor response to chemotherapy and radio-
therapy for breast cancer, we found that overexpression of
miR-638 impaired DNA repair in breast cancer cell lines,
which suggests that miR-638 might correspond to the cel-
lular stress upon radiation and DNA-damaging agents.
Conclusions
We previously found that miR-638 was one of the most
deregulated miRNAs in breast cancer progression. In
present work, we demonstrated that miR-638 directly regu-
lates BRCA1 expression in breast cancer, implying a critical
role of miR-638 in the course of breast carcinogenesis and
biological behaviors. miR-638 exerts distinct effects on cell
proliferation and invasion in different types of breast can-
cer. In addition, miR-638 enhanced radiation and chemo-
therapy sensitivity in TNBC cells by regulating BRCA1
expression via DNA repair pathways. Taken together, miR-
638 may serve as a potential prognostic biomarker and
therapeutic target for breast cancer.
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Figure 5 Effects of miR-638 on DNA repair capability by host cell reactivation (HCR) assay. Cells were transiently co-transfected by miR-638
mimic or inhibitor with pCMU-Luc vector pre-damaged by UVC, or anticancer drugs for the evaluation of DNA repair capacity. In (A) and (B),
MDA-MB-231 and Hs578T exhibited significantly reduced luciferase activity, while MCF-7 cell lines showed increased luciferase activity in miR-638
mimic-transfected cells, but there were no changes in T47D and MCF-10A when co-transfected with either miR-638 mimic or inhibitor with pCMU-Luc
vector pre-damaged by UVC or cisplatin. (C) Cells were co-transfected with miR-638 mimic or inhibitor with pCMU-Luc vector pre-treated with 5-FU.
Reduced DNA repair capability was only observed in Hs578T cells but not in MDA-MB-231, MCF-7, T47D and MCF-10A cell lines. (D) Cells were
co-transfected with miR-638 mimic or inhibitor and pCMU-Luc vector pre-treated with epirubicin. No significant DNA repair capability changes were
observed in all cell lines. Results are displayed as mean data ± SE (*P <0.05, **P <0.01). 5-FU, 5-fluorouracil.
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